Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 2/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361530 | 0.91 | LRRK2 (0.49) | ARMDM2GSK3BLRRK2HSP90AA1 | |
| SCHEMBL5365740 | 0.85 | PTPN1 (0.51) | MDM2LRRK2 | |
| SCHEMBL5366592 | 0.84 | LRRK2 (0.48) | MDM2LRRK2HSP90AA1 | |
| SCHEMBL7131374 | 0.81 | GSK3B (0.49) | ARMDM2GSK3BLRRK2TYR | |
| SCHEMBL5362880 | 0.81 | PLK4 (0.57) | ARLRRK2 | |
| SCHEMBL5358386 | 0.81 | NTRK1 (0.64) | MDM2LRRK2MAOB | |
| SCHEMBL5373669 | 0.79 | SRC (0.48) | — | |
| SCHEMBL7136343 | 0.79 | MEN1 (0.50) | MDM2LRRK2 | |
| SCHEMBL5363330 | 0.79 | MAP3K7 (0.43) | MDM2LRRK2 | |
| SCHEMBL5366869 | 0.79 | IGF1R (0.56) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | AR 1805/4885MDM2 888/4885GSK3B 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.